In stock COA-35%
In stock COA DOCUMENT SLOT-35%
Metabolic ResearchCagriSema
Combination research compound (Semaglutide + Cagrilintide) — dual GLP-1/amylin pathway agonist studied for synergistic metabolic effects.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundCagriSema
Presentation10mg vial
CategoryMetabolic Research
AvailabilityIn stock
Batch COACertificate supplied with order
You save €210.00 on this presentation — an extra 10% off when you pay with crypto.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
CagriSema is a combination research compound pairing semaglutide (a GLP-1 receptor agonist) with cagrilintide (a long-acting amylin analog) in a single preparation. Developed by Novo Nordisk, it exploits the complementary mechanisms of two distinct satiety hormone pathways. Phase 3 clinical data demonstrated approximately 20% average weight loss — significantly greater than either component alone — making it one of the most effective metabolic research combinations studied to date. The combination reflects a broader trend in metabolic research toward multi-receptor engagement.
Mechanism of Action
CagriSema engages two distinct anorexigenic pathways simultaneously. Semaglutide activates GLP-1 receptors on hypothalamic neurons (POMC/CART activation, NPY/AgRP inhibition), delays gastric emptying, and enhances glucose-dependent insulin secretion. Cagrilintide activates amylin receptors (AMY1-3) in the area postrema and hypothalamus — distinct neuronal populations that include histaminergic and dopaminergic circuits not reached by GLP-1 signalling. The non-overlapping central pathways produce additive appetite suppression, while both components independently delay gastric emptying and modulate glucagon release.
Research Applications
- Multi-receptor metabolic pathway synergy research
- GLP-1 and amylin receptor crosstalk studies
- Combination compound pharmacokinetics investigation
- Appetite regulation through complementary neuronal circuits
- Comparative efficacy studies vs mono-agonist approaches
FREE TOOL
Reconstitution calculator
Enter your reconstitution to get the draw volume for CagriSema.
Concentration5.00 mg/ml
Draw volume0.050 ml
On the syringe5.0 units
Doses per vial40
5units
Pull the plunger to 5.0 units on a 1 ml U‑100 syringe0.050 ml · 5.00 mg/ml · 40 doses per vial
Concentration = peptide mass ÷ water volume. Unit readings assume U-100 insulin syringes, graduated 100 units per millilitre. For laboratory calculation only — not dosing guidance.